Skip to main content

Table 1 Patient characteristics

From: Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohort study

Variables n 365 (100%)
Age at diagnosis; years
 Mean 62
 Range 25–80
 < 63 189 (51.8%)
 ≥ 63 176 (48.2%)
 > 70 56 (15.3%)
Gender
 Female 176 (48.2%)
 Male 189 (51.8%)
Body mass index (kg/m2)
 Median 26.4
 Range 15 (6–44)
 ≤ 18,5 13 (3.6%)
 18,5-24,9 128 (35.1%)
 ≥ 25,0 224 (61.4%)
Diabetes mellitus
 No 325 (89%)
 Yes 40 (11%)
Histology
 Adenocarcinoma not otherwise specified (NOS) 304 (83.3%)
 Mucinous adenocarcinoma 54 (14.8%)
 Adenocarcinoma of cylindrical cells 2 (0.5%)
 Signet ring adenocarcinoma 2 (0.5%)
 Adenosquamous carcinoma 1 (0.3%)
 Undifferentiated carcinoma 2 (0.5%)
Histopathology grade (G)
 G1 (well differentiated) 33 (9.0%)
 G2 (moderate differentiated) 279 (76.4%)
 G3 (poor differentiated) 52 (14.2%)
 No data 1 (0.3%)
Primary tumor classification (pT)
 1 3 (0.8%)
 2 47 (12.9%)
 3 249 (68.2%)
 4a 48 (13.2%)
 4b 18 (4.9%)
Regional lymph nodes classification (pN)
 1a 106 (29.0%)
 1b 119 (32.6%)
 1c 1 (0.3%)
 1 1 (0.3%)
 2a 80 (21.9%)
 2b 58 (15.9%)
Number of harvested lymph nodes
 < 12 196 (53.7%)
 ≥ 12 165 (45.2%)
 No data 4 (1.1%)
Primary tumor location
 Ceacum 64 (17.5%)
 Ascending colon 49 (13.4%)
 Hepatic flexure 28 (7.7%)
 Transverse colon 20 (5.5%)
 Splenic flexure 22 (6.0%)
 Descending colon 14 (3.8%)
 Sigmoid colon 168 (46.1%)
Primary tumor location
 Right colon 161 (44.1%)
 Left colon 203 (55.6%)
 No data 1 (0.3%)
Surgery
 Right hemicolectomy 116 (31.8%)
 Right hemicolectomy extended 36 (9.9%)
 Left hemicolectomy 45 (12.3%)
 Sigmoidectomy 167 (45.8%)
 Transversectomy 1 (0.3%)
Adjuvant chemotherapy
 FOLFOX-4 336 (92%)
 CAPOX (XELOX) 29 (8%)
CEA concentration before surgery; ng/ml
 < 5 96 (26.3%)
 ≥ 5 28 (7.7%)
 No data 241 (66.0%)
CEA concentration after surgery; ng/ml
 < 5 292 (80.0%)
 ≥ 5 33 (9.0%)
 No data 40 (11.0%)